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Prion depletion and preservation of biological activity by
preparative chaotrope ultracentrifugation
Abstract
Prions are characterized by unusual physicochemical properties, such as insolubility and resistance to
proteases, and maintain infectivity after contact with disinfectants and decontamination procedures
active against conventional pathogens. To date, most methods for prion inactivation are either
incomplete or unacceptably harsh for the purification of fragile biotherapeutics. Here we describe a
simple prion removal procedure that takes advantage of differential sedimentation and denaturation of
prions. Prion-spiked fluids were layered onto an intermediate sucrose cushion and an 8M urea solution,
and subjected to single-step ultracentrifugation. Due to their insolubility, prions rapidly traveled through
the sucrose cushion into the urea solution. Prion infectivity in the upper phase was reduced by at least
3.2 logs, or up to 6 logs or more. Very little soluble protein was lost from the input sample and a
proof-of-principle experiment demonstrated only marginally reduced biological activity of spiked
enzyme after ultracentrifugation. This procedure is likely to synergize with nanofiltration and other
prion removal steps in the treatment of batches of raw and semifinal biopharmaceutical materials.
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Abstract 
Prions are characterized by unusual physicochemical properties, such as insolubility and 
resistance to proteases, and maintain infectivity after contact with disinfectants and 
decontamination procedures active against conventional pathogens. To date, most methods 
for prion inactivation are either incomplete or unacceptably harsh for the purification of fragile 
biotherapeutics. Here we describe a simple prion removal procedure that takes advantage of 
differential sedimentation and denaturation of prions. Prion-spiked fluids were layered onto 
an intermediate sucrose cushion and an 8M urea solution, and subjected to single-step 
ultracentrifugation. Due to their insolubility, prions rapidly traveled through the sucrose 
cushion into the urea solution. Prion infectivity in the upper phase was reduced by at least 
3.2 logs, or up to 6 logs or more. Very little soluble protein was lost from the input sample 
and a proof-of-principle experiment demonstrated only marginally reduced biological activity 
of spiked enzyme after ultracentrifugation. This procedure is likely to synergize with 
nanofiltration and other prion removal steps in the treatment of batches of raw and semifinal 
biopharmaceutical materials. 
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Introduction 
Prions are infectious agents causing invariably fatal neurodegenerative diseases, such as 
Creutzfeldt-Jakob disease (CJD) in humans, bovine spongiform encephalopathy (BSE) in 
cattle, and scrapie in sheep and goats [1, 2]. Prions are characterized by certain unusual 
physicochemical properties, and, in particular, by their strong resistance to common 
procedures of decontamination used against conventional microorganisms [3]. According to 
the protein-only hypothesis, PrPSc, and abnormally folded and aggregated isoform of the 
host-encoded cellular prion protein PrPC, constitutes the major component of the prion [4]. 
Efficient physicochemical decontamination methods for most strains of prions include 
exposure to 1 M sodium hydroxide for one hour at room temperature, porous-load 
autoclaving at ≥134 °C for at least 60 min, or gravity-displacement autoclaving at 132 °C for 
one hour [5]. Sodium hypochlorite solutions containing 20’000 ppm of available chlorine have 
also been reported to be effective [6, 7]. Furthermore, combining exposure to sodium 
hydroxide with autoclaving has been described to completely eliminate prion infectivity [8]. 
However, biological materials typically do not withstand the harsh or denaturing methods that 
would guarantee complete inactivation of prions. Hence alternative approaches are required 
for efficient and substantial reduction of the infectious agent in a milder fashion, such that 
native properties of the biological to be processed are maintained intact. For the production 
of therapeutics from blood, plasma or other biological fluids such as urine or tissue extracts, 
the purified compounds need to be separated from the prions during biomanufacturing 
processes such that biological activity of the desired therapeutic is assured. Many attempts 
to remove prions from biological materials have been performed using precipitation, 
chromatography, and filtration [9-12]. During the manufacturing or isolation processes of 
therapeutic compounds from biological fluids, it is desirable to combine several of these 
steps consecutively, since none of them guarantees complete removal of prions.  
Non-denaturing prion removal approaches are not only required for the production of 
therapeutics, but also for decontamination of samples for research purposes. This is 
particularly important when downstream analytical procedures need to be performed outside 
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a designated biosafety laboratory. This is often the case when bulky or extremely expensive 
apparatuses, such as e.g. mass spectrometers, liquid chromatography units, nuclear 
magnetic resonance spectroscopes, cannot be hosted within biosafety laboratories. 
The aim of this study was to establish an alternative approach to the decontamination 
techniques described above, using milder procedures that may be applicable to delicate 
biological samples. Towards this goal, we strived to establish a preparative technique that 
would be suitable for the removal of the infectious agent from biological fluids or tissue 
extracts containing soluble proteins or other small non-proteinaceous molecules of interest, 
such as metabolites. Ultracentrifugation was shown to efficiently sediment the infectious 
prion agent [13, 14]. The principle underlying the procedure described here is that prions 
contained in biological fluids will sediment during ultracentrifugation. This property is derived 
from the aggregated nature of PrPSc, and can be exploited to reduce – or possibly clear – the 
infectious agent from the solution containing the biological of interest. 
We reasoned that using a step gradient with a denaturing bottom fraction would inactivate 
prions that were sedimented by ultracentrifugation, while leaving compounds in the top 
fraction biologically active. The primary advantage of the non-denaturing removal procedure 
described in this study is that specialized equipment, such as nanofiltration or 
chromatography devices, is not required. Another noteworthy aspect is that this technique 
avoids precipitation of the sample by organic compounds such as acetone or trichloroacetic 
acid, which may potentially lead to irreversible inactivation of biologically active proteins, or to 
undesired coprecipitation of the molecules of interest along with the infectious prions. As with 
most other “soft” prion removal technology, complete sterilization was not always achieved, 
yet the reduction factors attained by step gradient ultracentrifugation were sufficient to 
warrant its use in combination with other technologies.  
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Materials and Methods 
Preparation of RML5 mouse scrapie and mock brain homogenates: Homogenates were 
prepared from terminally scrapie-sick CD1 mice that had been inoculated with passage 4.1 of 
the RML mouse prion strain (RML5 infectious inoculum), or from healthy CD1 mice (mock 
inoculum). Brains were homogenized in 10 volumes of 0.32M Sucrose with a Polytron 
homogenizer. Homogenates were clarified for 1h at 1’000g, and aliquots of the supernatant 
were frozen at –80 °C. 
 
Ultracentrifugation: Ultracentrifugation was performed in a Sorvall Discovery M150E 
centrifuge using a Sorvall S55S swinging bucket rotor (ravg 6.1 cm). Centrifugation was 
performed at 40’000rpm (RCF=110’000g) for 2 hrs at 4 °C. The top fraction (10mg/ml BSA 
(Sigma, USA) in PBS) was spiked with 10% of RML5 mouse scrapie brain homogenate 
(1:10). The intermediate fraction consisted of 10% sucrose (Sigma) containing bromophenol 
blue (Merck, USA), whereas the bottom fraction was composed of 8 M urea in water (Sigma, 
USA). Fractions were loaded from top to bottom: 1 ml of the top fraction was carefully 
pipetted into the ultracentrifuge tube. Using a 1 ml syringe with a long needle 0.5 ml of the 
intermediate fraction was carefully added to the bottom of the tube, followed by 0.5 ml of the 
bottom fraction. After centrifugation, fractions where collected from top to bottom (Fig. 1). 
Firstly, 0.5 ml were removed from the top fraction (T1). This was followed by the second 0.5 
ml of the top fraction (T2), the intermediate fraction (I) and the bottom fraction (B). 
 
Sodium phosphotungstate (PTA) precipitation: PTA precipitation was performed similarly to 
previous reports [15]. PBS (50 μl) was added to 450 μl of each sample, and followed by the 
addition of an equal volume of 4% Sarkosyl in PBS. The samples were then mixed, and 
incubated for 15 min at 37°C under constant agitation. Benzonase and MgCl2 were added to 
a final concentration of 50 U/ml and 12.75 mM, respectively, and samples were incubated for 
30 min at 37°C under continuous agitation. Pre-warmed PTA (pH 7.4) was added to a final 
concentration of 0.3%, and samples were incubated at 37°C for 30 min with constant 
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agitation, followed by centrifugation at 37°C for 30 min at maximum speed in a benchtop 
Eppendorf microcentrifuge. Resultant pellets were resuspended in 20μl PBS containing 0.1% 
Sarkosyl, and digested with proteinase K (PK; 50 μg/ml) for 1h at 37°C under continuous 
agitation. Samples were heated at 95°C for 5 min in SDS-containing loading buffer prior to 
gel loading.  
 
Western blot analysis: Samples were electrophoresed through 12% NuPAGE Bis-Tris 
polyacrylamide gels (Invitrogen, USA) at 150V MES running buffer (Invitrogen). Transfer was 
performed for 2h at 110V in transfer buffer (25mM Tris, ph 8.3, 0.19M glycine, 20% 
methanol) onto nitrocellulose membranes (Schleicher-Schuell, Germany). Membranes were 
blocked with TBS-T containing 5% Topblock (Juro, Switzerland), incubated with monoclonal 
anti-mouse PrP POM1 antibody [16], diluted 1:3000 in TBS-T containing 1% Topblock, at 
4°C overnight. For detection, HRP coupled rabbit-anti mouse IgG1 antibody (Zymed, USA) 
was used at a dilution of 1:10.000 in TBS-T, containing 1% Topblock. Following incubation in 
Supersignal ECL reagent (Pierce, USA), membranes were exposed to ECL Hyperfilm 
(Amersham, UK). 
 
Coomassie blue staining: Each sample (amounts as indicated) was electrophoresed through 
12% NuPAGE gel. Following electrophoresis, gels were transferred to a Coomassie blue 
bath (0.025% Coomassie Blue R250, 40% Methanol, 7% acetic acid) and incubated for 2 
hrs. Gels were subsequently destained in several changes of 40% methanol and 7% acetic 
acid for several hours. 
 
Dialysis: Samples from fractions (I) and (B) were dialyzed prior to use in cell culture 
experiments, using Slide-A-Lyzer Dialysis Cassettes with 3.5kD molecular weight cut-off, 0.1 
- 0.5 ml capacity (Pierce, USA). Dialysis was performed for 2h at room temperature against 2 
l of PBS, with two changes of the dialysis buffer. 
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Scrapie cell assay in endpoint format (SCEPA): Cells were cultured in Optimem (GIBCO, 
USA) containing 10% fetal calf serum (Hyclone, Perbio, Switzerland), 2mM L-glutamine in 
the presence of 10.000 U/ml Penicillin and 100μg/ml Streptomycin (Invitrogen, USA). For 
SCEPA, highly prion-susceptible neuroblastoma cells (subclone N2aPK1 [17]) were exposed 
to prion-containing samples in 10-fold dilutions for 3 days in 96-well-plates. Cells were split 
three times 1:3 every two, and three times 1:10 every three days. After reaching confluence, 
25’000 cells from each well were filtered onto the membrane of an ELISPOT plate (Millipore), 
treated with proteinase K (PK), denatured using 3M GdHCl, and individual infected (PrPSc-
positive) cells were detected by in situ immunocytochemistry using monoclonal antibody 
POM1 to PrP in a 1:50 dilution. Wells were scored positive if the spot number, as assessed 
by visual inspection, exceeded the background in cells incubated with mock homogenate. 
The prion infectivity titers (Tissue culture infectivity dose: TCID50) were calculated from the 
numbers of negative and total wells using the statistical treatment of Reed and Muench [18]. 
The number of “infectious tissue culture units (TCI)” per aliquot was calculated using the 
Poisson equation. The exquisite sensitivity of the SCEPA in the format used here is based on 
the fact that the proportion of infected cells, and with it the signal-to-background ratio, 
increases on average about 25% per day during culturing [17].  
 
Infectivity bioassays with tga20 indicator mice: From each sample 30 µl was inoculated 
intracerebrally into each of four tga20 mice, which overexpress PrPC and are utilized as 
sensitive indicators for prion infectivity [19]. Infectivity titers were calculated using the 
relationship y=11.45-0.088x (y, logLD50 per ml of homogenate; x, number of days from 
inoculation to terminal disease) which had been derived from titrations of standard inocula as 
described [20]. 
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Horseradish-peroxidase (HRP) activity measurement: The top fraction (10mg/ml BSA 
(Sigma, USA) in PBS) was spiked with 10% of RML5 mouse scrapie brain homogenate 
(1:10) and 1μl (1:3000) rabbit-anti-mouse IgG coupled to horseradish-peroxidase (HRP; 
Zymed/Invitrogen, USA). Intermediate and bottom fraction as well as ultracentrifugation were 
performed as described. After ultracentrifugation HRP activity was measured by luminometry 
after addition of a chemiluminescent substrate (SuperSignal ELISA Pico; Pierce, USA) in the 
input (Ipt) as well as in all fractions after ultracentrifugation. PBS served as a negative 
control. Two independent experiments were performed where three replicates per fraction 
were measured.  
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Results 
Step gradient layers remain separated after ultracentrifugation. 
We performed zonal ultracentrifugation using a step gradient consisting of three layers of 
increasing density (Fig. 1). The bottom layer (B) was of high density and contained 
chaotropes in sufficient concentration for inactivation of prions. In the experiments described 
here, 8 M urea was used [21] because it is relatively non-toxic and can be utilized in the 
manufacturing of biologicals, but other chaotropes could also conceivably be used. The 
bottom layer was overlaid with an intermediate layer (I), which consisted of a solution with 
density (10% sucrose) intermediate between that of the top and the bottom layers. For the 
purpose of visualization, the intermediate layer contained bromophenol blue. The top layer 
(T) had the lowest density and consists of the biological sample to be decontaminated. 
Importantly, the intermediate layer was utilized to ensure separation of the denaturing bottom 
layer from the top layer containing the biological of interest.  
Ultracentrifugation of the discontinuous gradient for 2h at 110.000g resulted in recovery of 
three intact fractions with minimal spreading of the top fraction (T) into the intermediate 
fraction (I), and very little contamination of the intermediate fraction with the bottom fraction 
(B).  
 
Minimal loss of soluble proteins from top layer. 
During the prion reduction procedure we strived to minimize any loss of proteins from the top 
fraction, as this fraction contained the components to be purified and/or analyzed in 
subsequent downstream procedures. In order to assess any potential protein losses, aliquots 
from each fraction were electrophoresed and gels were stained with Coomassie blue to 
visualize protein composition of each gradient layer. Fig. 2 shows the proteins present in the 
different fractions of an experiment performed with bovine serum albumin (BSA) in the top 
layer. Predominant amounts of protein were observed in the top layer (T1, T2) after 
ultracentrifugation. Only small amounts of protein were found to have migrated or diffused to 
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the intermediate (I) or bottom fraction (B), whereas the bulk of protein was stationary to the 
top phase. 
 
Efficient removal of PrPSc following step gradient ultracentrifugation. 
To assess the removal of PrPSc in the top layer following ultracentrifugation, we performed 
western blot analyses of samples from each layer (T1, T2, I, B) following ultracentrifugation, 
and compared them to the top layer prior to ultracentrifugation (Fig. 3A). To distinguish 
between PrPC and PrPSc we digested 20μl of each fraction with PK where indicated. In two 
independent experiments, we were unable to detect PrPSc in aliquots of the top layer (T1, 
T2), even after overexposure for 3 hr (Fig. 3A). Furthermore, no PrPSc was detected in the 
intermediate layer (I). In one experiment we detected traces of PrPSc in the bottom fraction 
(B) (Fig. 3A), whereas in a second experiment we were not able to detect PrPSc in the bottom 
fraction (data not shown). As expected, large amounts were present in the top fraction (Ipt) 
before centrifugation. Notably, the bottom fraction (B) exhibited a strong signal for PrPC, 
comparable to the PrP signal in the top fraction prior to ultracentrifugation (Ipt). To increase 
the sensitivity of the Western blot assay for PrPSc we performed a phosphotungstic acid 
precipitation using a total volume of 450μl for each fraction. This was found to lead to an 
approximately twenty-fold enhancement in sensitivity. In two independent experiments we 
could detect PrPSc signals in precipitates of the intermediate and the bottom fractions (Fig. 
3B). Small amounts were also detected in one of two analyses of the T2 fraction (Fig. 3B left 
panels) and possible traces were also found in the T1 fraction of the second experiment (Fig. 
3B right panels). 
 
Reduction of prion infectivity by step gradient ultracentrifugation. 
Since the amount of PrPSc does not always correlate directly with the level of infectivity [22], 
we performed a scrapie cell assay of the different fractions after ultracentrifugation to assess 
the reduction factor in prion infectivity titers. Fractions I and B were dialyzed prior to SCEPA 
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to remove urea, which would have been toxic to neuroblastoma cells. Dialysis was chosen 
rather than dilution in order to maintain a maximal sensitivity of the assay and avoid possible 
false negatives in the post-procedure readout. Importantly, we have shown that the 
procedure of dialysis does not reduce prion infectivity in a given sample [23]. If anything, 
nominal infectivity tends to increase after dialysis, possibly because of the removal of small-
molecular inhibitory constituents of brain homogenate. Hence, log reduction calculations 
based on SCEPA after dialysis are most certainly not overoptimistic.  
Two independent experiments with the same input infectivity were carried out in order to 
estimate the reproducibility of the method. As prion spike, we used the mouse-adapted 
Rocky Mountain Laboratory scrapie strain “RML5”. The titer of this homogenate had been 
previously ascertained in a mouse bioassay [24]. As shown in Table 1, the prion titer in the 
top layer prior to ultracentrifugation was approximately 7 log TCI units/ml. After 
ultracentrifugation, fractions were collected from top to bottom. In two experiments performed 
on different weeks, there was a reduction of prion infectivity in the top fraction by 6.1 (T1) 
and 4.8 (T2) in experiment 1 and by 5.2 (T1) and 4.5 (T2) log TCI units/ml in experiment 2. 
Prion infectivity in the intermediate fraction (I) was 2.2 and 1.6 log TCI units/ml whereas 
infectivity in the bottom phase (B) reached values of 2.2 and 2.6 log TCI units/ml, 
respectively.  
To verify these results in a second paradigm, we measured prion infectivity in the different 
fractions after ultracentrifugation by mouse bioassay utilizing tga20 mice, which overexpress 
Prnp and represent a convenient and relatively fast model for sensitive detection of prions 
[25]. Dialyzed fractions I and B were inoculated intracerebrally (i.c.) into tga20 indicator mice, 
which were subsequently monitored for signs of prion disease. Again, the same input was 
used in two temporally independent experiments, with mouse scrapie brain homogenate 
RML5 as a prion spike. As shown in Table 2, the prion titer in the top layer prior to 
ultracentrifugation was approximately 6.6 log LD50 units/ml. After ultracentrifugation, fractions 
were collected from top to bottom. In two experiments performed there was a reduction of 
prion infectivity in the top fraction by 4.3 (T1 and T2) in experiment 1 and by 3.6 (T1) and 3.2 
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(T2) log LD50 units/ml in experiment 2. Prion infectivity in the intermediate fraction (I) was 3.7 
and 4.1 log LD50 units/ml whereas infectivity in the bottom phase (B) reached values of 3.0 
and 3.6 log LD50 units/ml.  
The sensitivity of the SCEPA assay, as performed here, was in the same order of magnitude 
of the mouse bioassay using tga20 transgenic mice [19]:  the nominal difference in sensitivity 
of approximately 0.5 logs lies within the standard error of the mouse bioassay (typically ±1 
log when performed with 4-6 mice/titration step). 
 
Preservation of enzyme activity after step gradient ultracentrifugation. 
We then went on to investigate whether the procedure presented here would be applicable to 
prion removal from biological fluids without impairment of compounds to be purified. Towards 
that goal, we investigated the impact of step gradient ultracentrifugation on a sample spiked 
with prions and horseradish-peroxidase (HRP; Fig. 4). A commercial HRP-antibody 
conjugate was used in order to simulate the purification of realistic macromolecules. In 
agreement with the experiments detailed above, step gradient ultracentrifugation once again 
resulted in removal of PrPSc from the top layers (T1 and T2) and no PK resistant PrP was 
detected in the intermediate (I) and bottom (B) fractions after ultracentrifugation as assessed 
by Western blot analysis (Fig. 4A). In stark contrast, approx. 70% of the input HRP activity 
remained in the top fractions. Less than 30% of the input enzyme activity was detected in the 
intermediate fraction, and only traces of enzyme activity were measured in the bottom 
fraction (Fig. 4B).  
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Discussion 
Prevention of iatrogenic transmission of infectious agents is crucial to the production of 
biotherapeutical compounds for human or veterinarian use. Preventive strategies are 
typically based on three pillars: (1) sourcing of uncontaminated raw materials, (2) sensitive 
diagnostic tests, and (3) removal and inactivation procedures. This is particularly important in 
the case of prions, for which no effective therapy exists.  
Furthermore, prion decontamination methods are required in biological research in order to 
avoid occupational exposure to TSE agents, and also to minimize contamination of 
expensive technical devices. One such example for the latter situation is the search for 
biomarkers of prion diseases in body fluids such as blood, urine, CSF, and saliva. Such 
markers would be invaluable for the early diagnosis of prion disease and/or for monitoring 
therapeutic efficiency of future treatments. However, approaches for the identification of 
biomarkers often involve the use of expensive equipment such as mass spectrometers or 
sophisticated chromatography devices, which are rarely not available to laboratories that 
have the biosafety status needed to handle prion agents and cannot be readily 
decontaminated with harsh standard prion disinfectants such as sodium hydroxide or 
hypochlorite [26]. 
Inactivation of prions by physical and/or chemical procedures is proverbially difficult to 
achieve [27, 28]. Those methods which are known to reliably inactivate prion agents are far 
too harsh to be used for direct treatment of biologically fragile active substances derived from 
serum, plasma, urine or cell culture products. Therefore, the spectrum of available methods 
for prion load reduction from biologicals is currently very limited. In practical terms, the only 
procedures that are typically available make use of certain precipitation methods, separation 
by chromatography, and/or removal by filtration. However, when employed as the only prion 
reduction strategy, most of these methods rarely guarantee highly efficient removal of prions 
[10, 12]. Therefore, a commonly used approach consists of using several of these methods 
sequentially. This approach works best if the chosen methods are “orthogonal”, i.e. they rely 
on fundamentally different physical principles: the sequential application of two methods 
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based on size-exclusion, each one of which may have a prion reduction power of 3 logs, will 
certainly not amount to 6 logs as the efficacy of the second step will have been preempted by 
the first step.  
Accordingly, there is a great need to invent additional methods of prion decontamination that 
are based on novel biophysical principles. For these reasons, we sought to develop an 
additional preparative procedure, which is suitable to deplete prions from biological samples, 
which could be used in biomedical research and, importantly, for the treatment of materials 
during the biomanufacturing process of therapeutics intended for use in humans. 
The prion removal procedure presented here is based on ultracentrifugation, in which prions 
contained in homogenates or biological fluids efficiently sediment during high-speed 
centrifugation, whereas soluble proteins of interest do not readily sediment. The biophysical 
underpinnings of this procedure rest on the presumption that prions consists obligatorily of 
protein aggregates [29]. Accordingly, it was reported that centrifugation of clarified 10% 
mouse scrapie brain or spleen homogenates at ω2t values of greater than 1.0 x 1011 rad2/s 
(centrifugation for 1h at 50.000 rpm with Beckman 50Ti rotor ravg5.9 cm) reduced the prion 
titer in the supernatant by approximately 4 logs [14]. Ultracentrifugation has the advantage 
that it allows soluble proteins or other compounds to remain in solution, whereas non-soluble 
or aggregated compounds such as prions will sediment.  
Previous studies of prion removal have typically made use of either brain homogenate or of 
microsomal fractions as spikes [30]. Since the actual biophysical structure of prion infectivity 
in blood or urine remains elusive, we opted for utilizing prion infectivity derived from brains of 
infected animals as an appropriate source of infectivity for this kind of studies. In agreement 
with this estimation, recent publication have concluded that there is no proof that any brain-
derived material is suitable or unsuitable for spiking [31]. For ultracentrifugation we used a 
step gradient as described in Fig. 1. As such, reduction of prion infectivity in the biological 
sample can be achieved by sedimentation and at the same time inactivation of sedimented 
prions occurs at the bottom of the tube. To avoid mixing of the urea fraction with the sample 
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used to derive biotherapeutics, we included an intermediate layer (10% sucrose) which 
physically separates the sample layer and the inactivation layer, but which can still be 
penetrated by prions. We chose urea as an inactivation solution since it has been 
established that incubation of prion containing preparations in 8 M urea leads to a reduction 
of prion infectivity by 5-6 logs [21]. Additionally, urea is a significantly milder denaturant and 
much less toxic than guanidinium thiocyanate or guanidium chloride. Sodium hydroxide is 
also a highly effective denaturant that is capable of sterilizing prions, but the chemical 
hazards associated with the handling of large amounts of sodium hydroxide rendered this 
decontaminant less attractive.  
By utilizing a step gradient ultracentrifugation procedure, we have achieved reduction of 
prion infectivity in the experimental samples by a factor of at least 3.2 logs. In some 
experiments, a reduction factor of >6 logs was found. Moreover, we found that only minimal 
soluble protein was lost from the input sample. Most importantly, bioactive compounds such 
as HRP were found to retain their biological activity after centrifugation and subsequent 
recovery from the top fraction.  
In the Western blot depicted in Fig. 3A, the signal for total PrP in the bottom fraction after 
centrifugation was similar to the signal for total PrP in the top fraction before centrifugation. 
This indicates efficient sedimentation of PrP. Despite similar amounts of PrP in the top phase 
before and the bottom phase after centrifugation, only relatively little PrPSc was detected in 
the bottom fraction compared to the large amount in the input. The finding that almost no 
PrPSc was detected by PTA precipitation in the top and only little in the intermediate fraction 
after centrifugation suggests that the majority of PrPSc had sedimented to the bottom phase 
and was rendered proteinase K sensitive by the urea in this fraction. Loss of PK resistance of 
PrPSc is usually accompanied by a reduction in prion infectivity [32]. This was reflected by the 
low infectivity titer in the bottom phase (2.2 - 2.6 log TCI units/ml or 3.0 – 4.1 log LD50 
units/ml), when compared to the top phase before centrifugation (6.7 log TCI units/ml or 6.6 
log LD50 units/ml). If inefficient inactivation of prions had taken place, the infectivity in the 
bottom fraction would have been similar to that contained in the top fraction prior to 
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ultracentrifugation. The 0.5 logs lower sensitivity of the SCEPA compared to the MBA in our 
study is most likely caused by biological variation of the susceptibility of the N2a subclone 
used [33]. 
Whilst absolute removal of prions was not achieved using the preparative procedure outlined 
here, our observed reduction of 3.2 - 6 logs represents a substantial minimization of prion 
infectivity and is similar, or in some cases superior, in its efficiency to other non-denaturing 
approaches reported by others. Certain nanofiltration procedures for example have 
accomplished reduction in prion infectivity between 1.6 and 5.9 logs, depending on the 
nature of the prion spike and the filters used [12, 34-36]. However, one problem with filtration 
is that filters tend to foul if tissue homogenates, solutions of high protein content or certain 
detergents are used [11]. In a well-performed study, ion exchange chromatography has been 
shown to decrease prion infectivity by 4-5 logs [10]. Whereas filtration or chromatography 
systems are routinely used by companies for the reduction of viruses in large scale 
manufacturing processes, they require specialized equipment, which is often not available in 
typical research laboratories. Precipitation has also been demonstrated to be useful for prion 
decontamination during manufacturing processes and reduction factors of 1–6 log LD50 units 
have been reported using methanol or ethanol in combination with acidic pH [10, 37, 38]. 
However, precipitation has the disadvantage that potential therapeutic proteins of interest 
might co-precipitate with prions (which is also disadvantageous for proteomics research 
studies) or that precipitated proteins may become inactivated by treatment with organic 
solvents. 
The method we have established might be used in prion research as prion depletion 
procedure for samples which contain low amounts of prions such as blood, urine or 
cerebrospinal fluid [39-41] or for fluids where infectivity has not yet been convincingly 
demonstrated, but which potentially contain low amounts of prions. If employed for samples 
containing high amounts of prions such as brain or spleen homogenates it should be used in 
conjunction with a second method. The method described here can also be applied to the 
isolation of therapeutics from biological samples of human or bovine origin. Importantly, 
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centrifugation is truly “orthogonal” to filtration procedures, and it can be very easily combined 
with e.g. nanofiltration in order to attain maximal prion load reduction.  
A further conclusion that can be drawn from this study is that the western blot assay for PrPSc 
alone is not sufficient for the validation of methods aiming at prion decontamination. We have 
demonstrated by using the PTA precipitation that the sensitivity of the Western blot assay for 
validation studies can be significantly increased. However, measuring the prion infectivity in a 
sample by bioassay remains the gold standard for such approaches. For validation studies 
where mouse prions are used as a prion spike, the scrapie cell assay in endpoint format 
represents a cost efficient and less time-consuming alternative to the mouse bioassay.  
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Figure legends and tables 
 
Figure 1: Preparative step gradient ultracentrifugation procedure. 
The upper fraction (T) consists of the biological sample to be decontaminated. It is separated 
by a fraction of intermediate density (I) from the denaturing bottom fraction (B). During 
ultracentrifugation the infectious prions will sediment to the bottom of the tube where they 
become inactivated. 
 
Figure 2: Distribution of proteins in step gradient layers before and after ultra-
centrifugation. 
Proteins from fractions T1-B after ultracentrifugation compared to proteins in the input (Ipt). 
Note the minimal loss of protein from the top fraction into the intermediate (I) or bottom (B) 
fractions. 
 
Figure 3: Efficient reduction of PrPSc by step gradient ultracentrifugation. 
A) Western blot of 20μl of each fraction T1-B after ultracentrifugation. After ultracentrifugation 
PrPSc can not be detected anymore in the top fractions T1 and T2. Ipt = top fraction before 
ultracentrifugation. Minimal amounts of PrPSc could be detected after centrifugation in the 
bottom phase (B) in the experiment presented here (long exposure). Note the strong signal 
for PrP in the bottom phase after centrifugation. 
B) Western blot after PTA precipitation of 450μl of each fraction T1-B after 
ultracentrifugation. Two representative experiments are shown. For the input sample only 
10μl were used. After PTA precipitation signals for PrPSc could be detected in the 
intermediate (I) and bottom (B) fractions of both experiments, whereas only minimal amounts 
were detected in fractions T1 and T2. 
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Figure 4: Preservation of enzyme activity after step gradient ultracentrifugation. 
A) Western blot of 20μl of each fraction T1-B after ultracentrifugation. After ultracentrifugation 
PrPSc can not be detected anymore in the top fractions T1 and T2. Ipt = top fraction spiked 
with prions and horseradish-peroxidase (HRP) coupled to antibodies before 
ultracentrifugation.  
B) Enzyme activity of each fraction T1-B after ultracentrifugation. Horseradish-peroxidase 
(HRP) activity was normalized to Ipt (input sample was spiked with prions and HRP coupled 
to antibodies) whereas PBS served as negative control. 
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Table 1: Prion infectivity in the different fractions after step gradient 
ultracentrifugation measured by SCEPA. 
Prion Infectivity Titre (log TCI* units/ml) 
Fraction Experiment 1 log Reduction† Experiment 2 log Reduction† 
Input‡ 6.7 (7.0)1  6.7 (7.0) - 
T1 0.6# (<1.5) 6.1 (>5.5) 1.5 (1.8) 5.2 (5.2) 
T2 1.9 (2.1) 4.8 (4.9) 2.2 (2.8) 4.5 (4.2) 
I 2.2 (2.3) - 1.6 (2.1) - 
B 2.2 (2.4) - 2.6 (3.1) - 
*One tissue culture infectivity (TCI) unit is the amount of infectivity needed to infect one well 
(=one infectious particle).  
‡Top fraction before ultracentrifugation 
† Reduction of prion infectivity titer in log TCI units/ml compared to input. 
#The detection limit of this bioassay was 0.6 log TCI units/ml or 4 TCI units/ml (1.5 log ID50 
units/ml calculated by the method of Reed and Muench [21]). 
 1in parentheses prion infectivity titers are given in log ID50 units/ml as calculated by the 
method of Reed and Muench [21] 
Experiments were performed with mouse scrapie brain homogenate RML5 that had been 
previously titered in a mouse bioassay. Sensitivity of SCEPA was approximately 0.5 logs less 
sensitive than the typical mouse bioassay.  
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Table 2: Prion infectivity in the different fractions after step gradient 
ultracentrifugation measured by mouse bioassay. 
Prion Infectivity Titre (log LD50 units/ml)* 
Fraction Experiment 1 log Reduction† Experiment 2 
log 
Reduction†
 dpi +/- Std log LD50/ml  dpi +/- Std log LD50/ml  
Input‡ 55 +/- 1 6.6 - 55 +/- 1 6.6 - 
T1 104 +/- 8 2.3 4.3 96 +/- 10 3.0 3.6 
T2 104 +/- 6 2.3 4.3 92 +/- 3 3.4 3.2 
I 88 +/- 2 3.7 - 84 +/- 4 4.1 - 
B 97 +/- 4 3.0 - 89 +/- 3 3.6 - 
 
* Prion infectivity titer was determined by i.c. inoculation of samples in tga20 indicator mice 
and subsequent monitoring for development of prion disease. Four mice per group were 
utilized. 
‡Top fraction before ultracentrifugation 
† Reduction of prion infectivity titer in log LD50/ml compared to input. 
Experiments were performed with mouse scrapie brain homogenate RML5 that had been 
previously titrated in a mouse bioassay.  
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